Amarin Expects More Growth in 2021, Stock Looks Like a Buy
Amarin Stock Drops After Vascepa Appeal Hearing
How Much Higher Can Amarin Stock Surge?
In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.
Amarin Stock Crashes as FDA Plans Panel Review
Yesterday, Amarin announced its receipt of a notice from the FDA about the agency’s plans for an advisory committee meeting on November 14.
Amarin’s Q2 Earnings and Robust 2019 Outlook
Amarin Corporation (AMRN) reported its Q2 2019 earnings yesterday. Here’s how the stock, investors, and peer pharma stocks reacted.
Amarin Stock Rises on Updated Fiscal 2019 Guidance
Yesterday, Amarin (AMRN) revised its 2019 revenue guidance upwards from $350 million to $380 million–$420 million due to higher-than-anticipated demand for Vascepa in the first half of 2019.
Label Expansion to Boost Revenue Growth for Amarin’s Vascepa
On March 28, Amarin (AMRN) issued a press release announcing the submission of an sNDA (supplemental new drug application) to the FDA seeking label expansion for Vascepa.
Comparing Revenue Growth Trends for AMRN and IOVA
In its first-quarter earnings conference call, Amarin (AMRN) reiterated its fiscal 2019 net revenue guidance of $350 million, which represents a YoY rise of more than 50%.
What Are Analysts Recommending for AMRN and IOVA in May?
The consensus recommendation for Amarin in May is a “strong buy,” while the consensus recommendation for Iovance Biotherapeutics is a “buy.”
Comparing Sangamo’s and Amarin’s Revenue Growth
Sangamo is conducting Phase 1/2 studies on SB-318 and SB-913 for treating MPS (mucopolysaccharidosis) I and MPS II inherited metabolic disorders, respectively.
Analysts’ Recommendations for Sangamo Therapeutics and Amarin
On April 5, Sangamo Therapeutics (SGMO) closed at $12.58, 3.62% above its previous closing price, 100.96% above its 52-week low of $6.26, and 38.78% below its 52-week high of $20.55.
Sarepta or Amarin: Who Is Controlling Expenses Better?
Amarin is expected to dedicate a much higher percentage of its total sales to SG&A but a lower percentage of its total sales to R&D activities as compared to Sarepta Therapeutics from fiscal 2019 to fiscal 2021.
Sarepta or Amarin: Who’s Expected to Post Faster Revenue Growth?
Wall Street analysts have projected Sarepta Therapeutics’ revenues to be $395.55 million, $611.37 million, and $1101.00 million, for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.
How Amarin’s Expenses Are Evolving in Fiscal 2019
In fiscal 2018, Amarin (AMRN) reported SG&A expenses of $227.0 million, a year-over-year rise of 69%.
Vascepa Demand Drove Amarin’s Revenue in Fiscal 2018
In fiscal 2018, Amarin (AMRN) reported revenues of $229.2 million, a year-over-year rise of 27%, mainly driven by rising demand for Vascepa.
What Wall Street Recommends for Amarin after Q4 2018 Results
On February 27, Amarin (AMRN) closed at $21.18, 5.85% higher than its previous closing price, 801.28% higher than its 52-week low of $2.35, and 9.24% below its 52-week high of $23.33.
Amarin or Novavax: Who’s Controlling Expenses Better?
In its investor presentation, Amarin (AMRN) highlighted the United States as its priority target market for commercializing Vascepa.
Amarin or Novavax: Which Will Report Faster EPS Growth?
In its investor presentation, Amarin (AMRN) highlighted the annual death toll attributable to cardiovascular disease in the United States to more than 800,000 while the yearly treatment cost is estimated at $555 billion.
Amarin or Novavax: Which Will Report Faster Revenue Growth?
With its 2018 unaudited results, as announced in an investor presentation, Amarin (AMRN) has guided for net total revenue in the range of $72 million–$76 million…
What Wall Street Recommends for Amarin and Novavax
On February 22, Amarin (AMRN) closed at $19.87, 14% higher than its previous closing price and 746% higher than its 52-week low of $2.35.
Why Ligand Pharmaceuticals Tanked 25%
Today, US pharmaceutical firm Ligand Pharmaceuticals (LGND) fell 25% from yesterday’s closing price to a low of $98.86 for the day.
Why Amarin Is Soaring in First Half of January
Amarin has been rising on rumors about pharmaceutical giant Pfizer (PFE) being interested in acquiring the company.
Amarin Expects Expenses to Rise in the Future
Amarin (AMRN) expects Vascepa to witness robust demand trends in fiscal 2019 driven by demonstrated efficacy of the drug coupled with the company’s increasing focus on creating awareness.
Amarin Is Expected to Become Profitable in Fiscal 2020
In a press release issued on January 4, Amarin (AMRN) has announced that it will be submitting a supplemental new drug application (or sNDA) to the FDA in fiscal 2019.
Amarin Expects Robust Revenue Growth Going Forward
In a press release issued on January 4, Amarin (AMRN) projected net total revenues in the range of $224 million to $228 million for fiscal 2018.
Vascepa May Prove a Solid Growth Driver for Amarin Corporation
As per Amarin’s (AMRN) investor presentation, the company aims to position Vascepa as a new treatment paradigm in the cardiovascular space.
Amarin: Analysts’ Recommendations and Target Price
Amarin is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting unmet demand in the cardiovascular space.
Manufacturing Production Remains Negative in the UK
With the decline in manufacturing output, the iShares MSCI United Kingdom ETF (EWU) has fallen 6.6% over the past month as of January 12.